Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Finished Goods (2016 - 2025)

Historic Finished Goods for Heron Therapeutics (HRTX) over the last 10 years, with Q3 2025 value amounting to $10.9 million.

  • Heron Therapeutics' Finished Goods rose 6079.39% to $10.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.9 million, marking a year-over-year increase of 6079.39%. This contributed to the annual value of $6.2 million for FY2024, which is 3710.8% down from last year.
  • Latest data reveals that Heron Therapeutics reported Finished Goods of $10.9 million as of Q3 2025, which was up 6079.39% from $11.0 million recorded in Q2 2025.
  • In the past 5 years, Heron Therapeutics' Finished Goods ranged from a high of $22.0 million in Q3 2022 and a low of $6.2 million during Q4 2024
  • For the 5-year period, Heron Therapeutics' Finished Goods averaged around $11.9 million, with its median value being $10.0 million (2023).
  • The largest annual percentage gain for Heron Therapeutics' Finished Goods in the last 5 years was 31960.45% (2021), contrasted with its biggest fall of 6106.82% (2021).
  • Over the past 5 years, Heron Therapeutics' Finished Goods (Quarter) stood at $6.3 million in 2021, then soared by 199.22% to $18.7 million in 2022, then tumbled by 47.0% to $9.9 million in 2023, then crashed by 37.11% to $6.2 million in 2024, then soared by 74.72% to $10.9 million in 2025.
  • Its last three reported values are $10.9 million in Q3 2025, $11.0 million for Q2 2025, and $8.5 million during Q1 2025.